A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Apixaban is non-inferior to warfarin in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The clinical use of apixaban in older patients is carefully regulated by the Health Insurance Review and Assessment Service in South Korea, due to a high bleeding risk. This study aimed to evaluate the patterns of apixaban use and medication adherence. A retrospective study was conducted using the electronic medical record (EMR). The study included patientsdoi:10.32429/jkshp.2019.36.1.004 fatcat:outayseh3jdmfgfzoubwwtxsxi